Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Lapatinib + Capecitabine + Vinorelbine in HER2-positive metastatic breast cancer
2008-000528-22Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Mar 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib, capecitabine and vinorelbine in breast cancer, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Progression-free survival. Started Mar 2009; status: active.
02
Drugs
lapatinibcapecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-000528-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000528-22.